Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis

PHASE4CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Hepatitis C Virus Infection
Interventions
DRUG

Sofosbuvir

Sofosbuvir 400 mg tablet administered orally once daily

DRUG

RBV

Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Trial Locations (17)

15240

Pittsburgh

19104

Philadelphia

21201

Baltimore

23249

Richmond

27705

Durham

30033

Decatur

33125

Miami

64128

Kansas City

75216

Dallas

77030

Houston

90073

Los Angeles

90822

Long Beach

92102

San Diego

94121

San Francisco

94394

Palo Alto

97239

Portland

06520

New Haven

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT02128542 - Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis | Biotech Hunter | Biotech Hunter